Neovacs and BioSense partner to develop and commercialise IFNa Kinoid in China

French-based Neovacs has signed a commercial licence option agreement with BioSense Global for the development and commercial rights of IFN α Kinoid vaccine to treat lupus and dermatomyositis in China.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news